Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Conditions

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Timeline

Apr 1, 2016 → Mar 22, 2024

NCT ID

NCT02754726

About Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine

Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine is a phase 2 stage product being developed by Bristol Myers Squibb for Untreated Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02754726. Target conditions include Untreated Metastatic Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02754726	Phase 2	Completed	Apr 1, 2016	Mar 22, 2024	Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Competing Products

15 competing products in Untreated Metastatic Pancreatic Ductal Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion	AbbVie	Phase 2	52
Onureg + Venetoclax	AbbVie	Phase 1/2	41
Acalabrutinib + Rituximab + Chlorambucil	AstraZeneca	Phase 3	77
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel	Merck	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine	Roche	Phase 2	52
Rituximab + ACVBP regimen plus Pegfilgrastim	Amgen	Phase 2	51
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
PF-08634404 + Chemotherapy + Nivolumab	Pfizer	Phase 2/3	64
Nivolumab + Relatlimab	Bristol Myers Squibb	Approved	84
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Pumitamig + Folfox + Capox + Nivolumab	Bristol Myers Squibb	Phase 2/3	64
Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX	Bristol Myers Squibb	Phase 2/3	64

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved